72 related articles for article (PubMed ID: 14670298)
1. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation.
McFarland BJ; Strong RK
Immunity; 2003 Dec; 19(6):803-12. PubMed ID: 14670298
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys.
Rupert PB; Buerger M; Girard EJ; Frutoso M; Parrilla D; Ng K; Gooley T; Groh V; Strong RK
Heliyon; 2024 Apr; 10(7):e28583. PubMed ID: 38586421
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biophysical characterization of natural polyreactivity in antibodies.
Borowska MT; Boughter CT; Bunker JJ; Guthmiller JJ; Wilson PC; Roux B; Bendelac A; Adams EJ
Cell Rep; 2023 Oct; 42(10):113190. PubMed ID: 37804505
[TBL] [Abstract][Full Text] [Related]
4. Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors.
Whalen KA; Rakhra K; Mehta NK; Steinle A; Michaelson JS; Baeuerle PA
MAbs; 2023; 15(1):2208697. PubMed ID: 37165468
[TBL] [Abstract][Full Text] [Related]
5. Identification of small-molecule protein-protein interaction inhibitors for NKG2D.
Thompson AA; Harbut MB; Kung PP; Karpowich NK; Branson JD; Grant JC; Hagan D; Pascual HA; Bai G; Zavareh RB; Coate HR; Collins BC; Côte M; Gelin CF; Damm-Ganamet KL; Gholami H; Huff AR; Limon L; Lumb KJ; Mak PA; Nakafuku KM; Price EV; Shih AY; Tootoonchi M; Vellore NA; Wang J; Wei N; Ziff J; Berger SB; Edwards JP; Gardet A; Sun S; Towne JE; Venable JD; Shi Z; Venkatesan H; Rives ML; Sharma S; Shireman BT; Allen SJ
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2216342120. PubMed ID: 37098070
[TBL] [Abstract][Full Text] [Related]
6. Spatially resolved in silico modeling of NKG2D signaling kinetics suggests a key role of NKG2D and Vav1 Co-clustering in generating natural killer cell activation.
Grewal RK; Das J
PLoS Comput Biol; 2022 May; 18(5):e1010114. PubMed ID: 35584138
[TBL] [Abstract][Full Text] [Related]
7. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes.
Fan J; Shi J; Zhang Y; Liu J; An C; Zhu H; Wu P; Hu W; Qin R; Yao D; Shou X; Xu Y; Tong Z; Wen X; Xu J; Zhang J; Fang W; Lou J; Yin W; Chen W
EMBO J; 2022 Dec; 41(2):e107739. PubMed ID: 34913508
[TBL] [Abstract][Full Text] [Related]
8. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
[TBL] [Abstract][Full Text] [Related]
9. convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting.
Landgraf KE; Williams SR; Steiger D; Gebhart D; Lok S; Martin DW; Roybal KT; Kim KC
Commun Biol; 2020 Jun; 3(1):296. PubMed ID: 32518350
[TBL] [Abstract][Full Text] [Related]
10. Diversification of human NK cells: Lessons from deep profiling.
Wilk AJ; Blish CA
J Leukoc Biol; 2018 Apr; 103(4):629-641. PubMed ID: 29350874
[TBL] [Abstract][Full Text] [Related]
11. NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.
Godbersen C; Coupet TA; Huehls AM; Zhang T; Battles MB; Fisher JL; Ernstoff MS; Sentman CL
Mol Cancer Ther; 2017 Jul; 16(7):1335-1346. PubMed ID: 28500232
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for recognition of cellular and viral ligands by NK cell receptors.
Li Y; Mariuzza RA
Front Immunol; 2014; 5():123. PubMed ID: 24723923
[TBL] [Abstract][Full Text] [Related]
13. New prospects on the NKG2D/NKG2DL system for oncology.
Ullrich E; Koch J; Cerwenka A; Steinle A
Oncoimmunology; 2013 Oct; 2(10):e26097. PubMed ID: 24353908
[TBL] [Abstract][Full Text] [Related]
14. NKG2D ligands as therapeutic targets.
Spear P; Wu MR; Sentman ML; Sentman CL
Cancer Immun; 2013; 13():8. PubMed ID: 23833565
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ligands for the NKG2D activating receptor.
Raulet DH; Gasser S; Gowen BG; Deng W; Jung H
Annu Rev Immunol; 2013; 31():413-41. PubMed ID: 23298206
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of mouse cytomegalovirus m152/gp40 interaction with RAE1γ reveals a paradigm for MHC/MHC interaction in immune evasion.
Wang R; Natarajan K; Revilleza MJ; Boyd LF; Zhi L; Zhao H; Robinson H; Margulies DH
Proc Natl Acad Sci U S A; 2012 Dec; 109(51):E3578-87. PubMed ID: 23169621
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15.
Ring AM; Lin JX; Feng D; Mitra S; Rickert M; Bowman GR; Pande VS; Li P; Moraga I; Spolski R; Ozkan E; Leonard WJ; Garcia KC
Nat Immunol; 2012 Dec; 13(12):1187-95. PubMed ID: 23104097
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into activation of antiviral NK cell responses.
Finton KA; Strong RK
Immunol Rev; 2012 Nov; 250(1):239-57. PubMed ID: 23046134
[TBL] [Abstract][Full Text] [Related]
19. Regulation of immune cell function and differentiation by the NKG2D receptor.
Zafirova B; Wensveen FM; Gulin M; Polić B
Cell Mol Life Sci; 2011 Nov; 68(21):3519-29. PubMed ID: 21898152
[TBL] [Abstract][Full Text] [Related]
20. Preparative Protein Production from Inclusion Bodies and Crystallization: A Seven-Week Biochemistry Sequence.
Peterson MJ; Snyder WK; Westerman S; McFarland BJ
J Chem Educ; 2011 Jul; 88(7):986-989. PubMed ID: 21691428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
